Akshay Punja’s Post

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GynecologicalCancer #CancerDiagnostics #GeneticCounseling #CancerRisk #DiagnosticKits #EarlyDetection #CancerScreening #PharmaceuticalMarket #ChemicalDrugs #Healthcare

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalOncology #MolecularDiagnostics #CancerResearch #BreastCancer #ProstateCancer #ColorectalCancer #CervicalCancer #PCR #MultiplexPCR #InSituHybridization

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalOvarianCancerDrugsMarket #OvarianCancerTreatment #CancerResearch #PharmaceuticalIndustry #CancerTherapeutics #PersonalizedMedicine #Healthcare #CancerCare #MedicalAdvancements #MarketOutlook

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalMolecularDiagnostics #CancerMarket #PharmacogenomicDiagnosis #LiquidBiopsy #RespiratoryCancer #DigestiveSystemCancer #UrinarySystemCancer #CirculatorySystemCancer #MotorSystemCancer #ReproductiveSystemCancer

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #PancreaticCancerDrugMarket #BileDuctCancerDrugMarket #CancerTreatment #PharmaceuticalIndustry #DrugDevelopment #VEGFR #PD1 #STAT3 #PancreaticCancer #Cholangiocarcinoma

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalPharmaceuticalMarket #SmallLymphocyticLymphoma #DrugDevelopment #HealthcareInnovation #PatientCare #MedicalResearch #PharmaceuticalIndustry #HealthcareSettings #TreatmentOptions #MedicalAdvancements

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalSolidTumorCancerTreatmentMarket #CancerResearch #Chemotherapy #TargetedTherapy #Immunotherapy #HormoneTherapy #SurgicalProcedures #BreastCancer #CervicalCancer #ColorectalCancer

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalTargetedDrugs #ColorectalCancer #PharmaceuticalMarket #CancerTreatment #TargetedTherapies #HospitalCare #SpecialtyClinics #CancerResearch #MedicalAdvancements #PatientCare

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalTherapeuticCancerVaccinesMarket #CancerTreatment #CancerVaccines #HealthcareIndustry #MedicalTechnology #CancerResearch #BladderCancer #BrainTumors #BreastCancer #LungCancer

📢Exciting News 📍 Today, Accord Biopharma, Inc. a subsidiary of Intas Pharmaceutical Ltd has gotten the acceptance of its #Biosimilar DMB-3115 which is proposed biosimilar to STELARA ® (ustekinumab) from #USFDA 📌Accord Biopharma, Inc. conducted multi-regional Phase-III clinical trail in patients with plaque psoriasis. The main focus of the study was the rate of change in the Psoriasis Area and Severity Index (PASI) to assess skin symptom improvement. 💊 STELARA®, a Janssen Biotech blockbuster, approved for psoriasis, psoriatic arthritis, Crohn's, and colitis. It raked in $13.9B in U.S. sales in 2022, ranking among top biologics. #Biosimilar #USFDA #ustekinumab #accordbiopharma #Intas https://lnkd.in/eQiVMPst